Oculis says its eye drops passed an early PhIII test. Researchers have to repeat it to win approval

Max Gelman

Senior Editor

A Swiss biotech focused on developing new eye treatments touted positive data from the first part of a multi-stage Phase III program Monday morning. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Oculis says its eye drops passed an early PhIII test. Researchers have to repeat it to win approval

Max Gelman

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers' schizophrenia drug fails Phase 3 trial for adjunctive treatment

Ascletis posts puzzling Phase 1 update on obesity pill

China’s biotech market is staging a comeback that US biotech can only wish for

Genentech vet launches ADC startup with $20M

With aims to become a 'generational biotech,' Zealand Pharma hires Lilly veteran as science chief

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Oculis says its eye drops passed an ear­ly PhI­II test. Re­searchers have to re­peat it to win ap­proval

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Oculis says its eye drops passed an early PhIII test. Researchers have to repeat it to win approval